Book/Share of Supernus Pharmaceuticals, Inc.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|CHKE Cherokee Inc.||NASDAQ > Consumer Non-Durables > Apparel||4.89|
|CAR Avis Budget Group, Inc.||NASDAQ > Consumer Services > Rental/Leasing Companies||4.89|
|PBPB Potbelly Corporation||NASDAQ > Consumer Services > Restaurants||4.89|
|INFN Infinera Corporation||NASDAQ > Public Utilities > Telecommunications Equipment||4.90|
|KRYS Krystal Biotech, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||4.90|
|WMS Advanced Drainage Systems, Inc.||NYSE > Capital Goods > Containers/Packaging||4.91|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||4.91|
|PCO Pendrell Corporation||NASDAQ > Miscellaneous > Multi-Sector Companies||879.05|
|WTM White Mountains Insurance Group, Ltd.||NYSE > Finance > Property-Casualty Insurers||938.42|
|DCIX Diana Containerships Inc.||NASDAQ > Transportation > Marine Transportation||1,903.21|
|SEB Seaboard Corporation||NYSEMKT > Finance > Investment Bankers/Brokers/Service||2,890.09|
|BRK-A Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||187,384.70|
|BRK-B Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||187,384.70|